Publications from the AffiliateMarketIngtools of Sciences, Engineering, and Medicine provide objective and straightforward advice to decision makers and the public. This site includes We Treat You (HMD) publications released after 1998. A complete list of HMD’s publications from its establishment in 1970 to the present is available as a PDF.
Released: February 19, 2009
The process for developing new drug and biologic products is extraordinarily expensive and time-consuming—many consider the traditional model to be unsustainable. Although large pharmaceutical companies may be able to invest in the development of blockbuster drugs because they can expect a large return on their investment, these same organizations, when developing drugs to treat rare and neglected diseases, are unable to rely on such returns. On June 23, 2008, the Institute of Medicine’s Forum on Drug Discovery, Development, and Translation held a public workshop, “Breakthrough Business Models: Drug Development for Rare and Neglected Diseases and Individualized Therapies,” which sought to explore new and innovative strategies for developing drugs for rare and neglected diseases.
Released: February 06, 2009
For many years, concerns about bioterrorism and emerging infectious diseases have drawn attention to the need for strong surveillance systems. Experts are working to develop new and better ways to detect these biological threats as quickly as possible. One effort in this area is the Department of Homeland Security’s BioWatch program. To evaluate the effectiveness of the BioWatch program, the Institute of Medicine (IOM) and National Research Council (NRC) convened the Committee on Effectiveness of National Biosurveillance Systems: BioWatch and the Public Health System. This interim report contains no findings and recommendations, but outlines the committee’s initial progress.
Released: January 23, 2009
The NCI-sponsored cooperative groups have made important contributions to improving treatment for many types of cancer, including breast, ovarian, colorectal, and childhood cancers. Cooperative group research has been instrumental in establishing innovative treatments that improve outcomes and quality of life. Despite these successes, the Cooperative Group Program has faced a number of challenges that threaten its effectiveness. To address this problem, the National Cancer Policy Forum (NCPF) convened a workshop titled “Multi-Center Phase III Clinical Trials and NCI Cooperative Groups” in , DC, on July 1-2, 2008. The purpose of the workshop was to outline the challenges that the public clinical cancer research enterprise faces, and to identify possible solutions to these challenges.
Released: December 22, 2008
One of the biggest threats today is the uncertainty surrounding the emergence of a novel pathogen or the re-emergence of a known infectious disease that might result in disease outbreaks with great losses of human life and immense global economic consequences. In June 2008, the Institute of Medicine’s and National Research Council’s Committee on Achieving Sustainable Global Capacity for Surveillance and Response to Emerging Diseases of Zoonotic Origin convened a workshop that addressed the reasons for the transmission of zoonotic disease and explored the current global capacity for zoonotic disease surveillance.
Released: December 11, 2008
Colorectal cancer screening remains low, despite strong evidence that screening prevents deaths. With the aim to make recommended colorectal cancer screening more widespread, the workshop discussed steps to be taken at the clinic, community, and health system levels.
Released: September 29, 2008
On June 25, 2008, the IOM Forum on Neuroscience and Nervous System Disorders hosted more than 70 of the leading neuroscientists in the world, for a workshop titled From Molecules to Minds: Challenges for the 21st Century. The objective of the workshop was to explore a set of common goals or “Grand Challenges” posed by participants that could inspire and rally both the scientific community and the public to consider the possibilities for neuroscience in the 21st century.
Released: September 24, 2008
On December 4 and 5, 2007, the Forum on Microbial Threats hosted a public workshop in , DC to consider the possible infectious disease impacts of global climate change and extreme weather events on human, animal, and plant health, as well as their expected implications for global and national security.
Released: September 15, 2008
Design Considerations for Evaluating the Impact of PEPFAR is the summary of a 2-day workshop on methodological, policy, and practical design considerations for a future evaluation of human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) interventions carried out under the President’s Emergency Plan for AIDS Relief (PEPFAR), which was convened by the Institute of Medicine (IOM) on April 30 and May 1, 2007.
Released: September 12, 2008
The National Children s Study (NCS) is planned to be the largest long-term study of environmental and genetic effects on children s health ever conducted in the United States. By archiving all of the data collected, the NCS is intended to provide a valuable resource for analyses conducted many years into the future. This report evaluates the research plan for the NCS, by assessing the scientific rigor of the study and the extent to which it is being carried out with methods, measures, and collection of data and specimens to maximize the scientific yield of the study.
Released: July 10, 2008
The Bill and Melinda Gates Foundation requested that the Institute of Medicine (IOM) conduct an independent assessment of the IPTi efficacy studies using sulfadoxine-pyrimethamine (IPTi-SP) that have been previously conducted by the IPTi Consortium. The IOM convened a committee to evaluate the evidence concerning IPTi-SP, which included addressing issues related to its utility and safety, as well as program management aspects of IPTi. The resulting letter report contains the findings, conclusions, and recommendations of the IOM committee.